Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with fabry disease

Genetics in Medicine

Volumn 11, Issue 4, 2009, Pages 256-264

  Lubanda, Jean Claude ^a   Anijalg, Ene ^b   Bzdúch, Vladimír ^c   Thurberg, Beth L ^d   Bénichou, Bernard ^e   Tylki Szymanska, Anna ^f  

^a CHARLES UNIVERSITY   (Czech Republic)

^b TARTU UNIVERSITY CLINICS   (Estonia)

^c Physics and Informatics   (Slovakia)

^d GENZYME CORPORATION   (United States)

^e Genzyme Europe   (France)

^f CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Agalsidase beta; Enzyme replacement therapy; Fabry disease; Globotriaosylceramide; galactosidase A

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; CERAMIDE TRIHEXOSIDE; GLOBOTRIAOSYLCERAMIDE; ISOENZYME;

ADULT; ARTICLE; BIOPSY; BLOOD; CHEMICALLY INDUCED DISORDER; CHILL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; ENDOTHELIUM CELL; FABRY DISEASE; FEVER; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY FUNCTION TEST; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; SKIN; TREATMENT OUTCOME; URINE;

ADULT; ALPHA-GALACTOSIDASE; BIOPSY; CHILLS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FABRY DISEASE; FEVER; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; ISOENZYMES; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; SKIN; TREATMENT OUTCOME; TRIHEXOSYLCERAMIDES; YOUNG ADULT;

EID: 70349316414     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181981d82     Document Type: Article

References (25)

1. Desnick RJ, Ioannou YA, Eng CM, Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet A, Sly W, Valle D, editors. Metabolic and molecular bases of inherited disease. New York: McGraw Hill, 2001:3733-3774.
2. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008;105:2812-2817.
3. Barbey F, Brakch N, Linhart A, et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 2006;26:839-844.
4. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med 2001;345:9-16.
5. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-722.
6. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-1557.
7. Wraith JE, Tylki-Szymanska A, Guffon N, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008;152:563-570.
8. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006;69:1216-1221.
9. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146:77-86.
10. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-1301.
11. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74.
12. Thurberg BL, Byers HR, Granter SR, et al. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004;122:900-908.
13. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002;62:1933-1946.
14. Roddy TP, Nelson BC, Sung CC, et al. Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy. Clin Chem 2005;51:237-240.
15. Kitagawa T, Ishige N, Suzuki K, et al. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab 2005;85:196-202.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461-470.
17. Benichou B, Goyal S, Sung C, Norfleet AM, O’Brien F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 2009;96:4-12.
18. DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000;47:229-233.
19. Sakuraba H, Igarashi T, Shibata T, Suzuki Y. Effect of vitamin E and ticlopidine on platelet aggregation in Fabry’s disease. Clin Genet 1987;31:349-354.
20. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008;94:319-325.
21. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004;66:1589-1595.
22. Ohashi T, Sakuma M, Kitagawa T, Suzuki K, Ishige N, Eto Y. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab 2007;92:271-273.
23. Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2007;2:e598.
24. Grabowski GA, Kacena K, Cole JA, et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 2009;11:92-100.
25. Eng CM, Wilcox WR, Waldek S, et al. Fabry Disease Registry: Baseline medical characteristics in a cohort of 1213 males and females. J Inherit Metab Dis 2007;30:184-192.